Role of the tumour necrosis family ligand APRIL in solid tumour development: Retrospective studies in bladder, ovarian and head and neck carcinomas

European Journal of Cancer

Volumn 44, Issue 15, 2008, Pages 2097-2100

  Mhawech Fauceglia, P ^a   Allal, A ^b   Odunsi, K ^a   Andrews, C ^c   Herrmann, F R ^d   Huard, B ^b,e  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c Hospital 3 Gates Circle   (United States)

^d Hopital de Geriatrie   (Switzerland)

^e UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Carcinoma; Inflammation; Proteoglycan

Indexed keywords

LIGAND; PROTEOHEPARAN SULFATE;

ARTICLE; BLADDER CARCINOMA; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR CELL; UPREGULATION;

CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13; UP-REGULATION; URINARY BLADDER NEOPLASMS;

EID: 53049109470     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.07.007     Document Type: Article

References (14)

1. Mackay F., Schneider P., Rennert P., and Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 21 (2003) 231-264
2. Jelinek D.F., and Darce J.R. Human B lymphocyte malignancies: exploitation of BLyS and APRIL and their receptors. Curr Dir Autoimmun 8 (2005) 266-288
3. Planelles L., Castillo-Gutierrez S., Medema J.P., et al. APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: prognostic relevance of APRIL for survival. Haematologica 92 9 (2007) 1284-1285
4. Schwaller J., Schneider P., Mhawech-Fauceglia P., et al. Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. Blood 109 1 (2007) 331-338
5. Hahne M., Kataoka T., Schroter M., et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 188 6 (1998) 1185-1190
6. Rennert P., Schneider P., Cachero T.G., et al. A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med 192 11 (2000) 1677-1684
7. Roth W., Wagenknecht B., Klumpp A., et al. APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis. Cell Death Differ 8 4 (2001) 403-410
8. Darce J.R., Arendt B.K., Wu X., and Jelinek D.F. Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol 179 11 (2007) 7276-7286
9. Ingold K., Zumsteg A., Tardivel A., et al. Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 201 9 (2005) 1375-1383
10. Hendriks J., Planelles L., de Jong-Odding J., et al. Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ 12 6 (2005) 637-648
11. Sasisekharan R., Shriver Z., Venkataraman G., and Narayanasami U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2 7 (2002) 521-528
12. Mhawech-Fauceglia P., Kaya G., Sauter G., et al. The source of APRIL up-regulation in human solid tumor lesions. J Leukocyte Biol 80 4 (2006) 697-704
13. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 6917 (2002) 860-867
14. Beauvais D.M., and Rapraeger A.C. Syndecans in tumor cell adhesion and signaling. Reprod Biol Endocrinol 2 (2004) 3